{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:08:31Z","timestamp":1785863311061,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-019-1918-7","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T14:03:04Z","timestamp":1559311384000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Gout, flares, and allopurinol use: a population-based study"],"prefix":"10.1186","volume":"21","author":[{"given":"Charlotte","family":"Proudman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E.","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Gonzalez-Chica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany K.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8289-4922","authenticated-orcid":false,"given":"Catherine L.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"issue":"11","key":"1918_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649\u201362.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"1918_CR2","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","volume":"74","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1918_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"Michael Chen\u2010Xu","year":"2019","unstructured":"Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK: Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and nutrition examination survey, 2007-2016. Arthritis Rheumatol 2019.\u00a0\n                    https:\/\/doi.org\/10.1002\/art.40807\n                    \n                  . [Epub ahead of print]","journal-title":"Arthritis & Rheumatology"},{"key":"1918_CR4","first-page":"5","volume":"45","author":"K Ting","year":"2015","unstructured":"Ting K, Hill C, Gill T, Tucker G. Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study. Intern Med J. 2015;45:5.","journal-title":"Intern Med J"},{"issue":"1","key":"1918_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","volume":"15","author":"T Bardin","year":"2017","unstructured":"Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1):123.","journal-title":"BMC Med"},{"issue":"1","key":"1918_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1136\/annrheumdis-2012-202421","volume":"73","author":"F Perez-Ruiz","year":"2014","unstructured":"Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73(1):177\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1918_CR7","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1093\/rheumatology\/kem150","volume":"46","author":"E Roddy","year":"2007","unstructured":"Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatol. 2007;46(9):1441\u20134.","journal-title":"Rheumatol"},{"issue":"Suppl 1","key":"1918_CR8","first-page":"eS2","volume":"82","author":"T Bardin","year":"2015","unstructured":"Bardin T, Voshaar MA, van de Laar MA. The human and economic burden of difficult-to-treat gouty arthritis. Joint Bone Spine. 2015;82(Suppl 1):eS2\u20138.","journal-title":"Joint Bone Spine"},{"key":"1918_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1477-7525-10-117","volume":"10","author":"PP Khanna","year":"2012","unstructured":"Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, Khanna D. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes. 2012;10:117.","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"1918_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, et al. 2012 American college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1918_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1918_CR12","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, et al. 2012 American college of rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447\u201361.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1918_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3899\/jrheum.150607","volume":"43","author":"S Vaccher","year":"2016","unstructured":"Vaccher S, Kannangara DR, Baysari MT, Reath J, Zwar N, Williams KM, Day RO. Barriers to care in gout: from prescriber to patient. J Rheumatol. 2016;43(1):144\u20139.","journal-title":"J Rheumatol"},{"issue":"7","key":"1918_CR14","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00296-013-2935-5","volume":"34","author":"S Horsburgh","year":"2014","unstructured":"Horsburgh S, Norris P, Becket G, Arroll B, Crampton P, Cumming J, Keown S, Herbison P. Allopurinol use in a New Zealand population: prevalence and adherence. Rheumatol Int. 2014;34(7):963\u201370.","journal-title":"Rheumatol Int"},{"issue":"2","key":"1918_CR15","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.clinthera.2016.12.011","volume":"39","author":"RT Keenan","year":"2017","unstructured":"Keenan RT. Limitations of the current standards of Care for Treating Gout and Crystal Deposition in the primary care setting: a review. Clin Ther. 2017;39(2):430\u201341.","journal-title":"Clin Ther"},{"issue":"7","key":"1918_CR16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4065\/81.7.925","volume":"81","author":"CA Sarawate","year":"2006","unstructured":"Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, Bakst AW. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81(7):925\u201334.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"1918_CR17","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/rheumatology\/keh679","volume":"44","author":"TR Mikuls","year":"2005","unstructured":"Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK general practice research database (GPRD). Rheumatol. 2005;44(8):1038\u201342.","journal-title":"Rheumatol"},{"issue":"5","key":"1918_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1136\/ard.2007.076182","volume":"67","author":"DH Solomon","year":"2008","unstructured":"Solomon DH, Avorn J, Levin R, Brookhart MA. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann Rheum Dis. 2008;67(5):609\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1918_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-007214","volume":"5","author":"R Jackson","year":"2015","unstructured":"Jackson R, Shiozawa A, Buysman EK, Altan A, Korrer S, Choi H. Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis. BMJ Open. 2015;5(6):e007214.","journal-title":"BMJ Open"},{"issue":"5","key":"1918_CR20","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3899\/jrheum.080487","volume":"36","author":"EQ Wu","year":"2009","unstructured":"Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E. Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol. 2009;36(5):1032\u201340.","journal-title":"J Rheumatol"},{"issue":"1","key":"1918_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/RHU.0b013e3181945d2c","volume":"15","author":"R Halpern","year":"2009","unstructured":"Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol. 2009;15(1):3\u20137.","journal-title":"J Clin Rheumatol"},{"key":"1918_CR22","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1002\/art.33369","volume":"64","author":"T Neogi","year":"2012","unstructured":"Neogi T, Chen C, Chaisson CE, Hunter DJ, Choi H, Zhang Y. Management of gout attacks in the community. Arthritis Rheum. 2012;64:S66.","journal-title":"Arthritis Rheum"},{"key":"1918_CR23","unstructured":"Population Research and Outcome Studies (PROS). The Health Omnibus Survey (HOS)\u00a0methodology. Brief report no. 2002-04. Adelaide: South Australian Department of Health; 2002."},{"key":"1918_CR24","unstructured":"Population Research and Outcome Studies Unit (PROS). Health omnibus survey (HOS) evaluation report 2006. Adelaide: South Australian Department of Health; 2006."},{"key":"1918_CR25","unstructured":"Febuxostat [\n                    http:\/\/www.pbs.gov.au\/medicine\/item\/10445R\n                    \n                  ]."},{"issue":"1","key":"1918_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41927-018-0020-0","volume":"2","author":"KE Castro","year":"2018","unstructured":"Castro KE, Corey KD, Raymond DL, Jiroutek MR, Holland MA. An evaluation of gout visits in the United States for the years 2007 to 2011. BMC Rheumatology. 2018;2(1):14.","journal-title":"BMC Rheumatology"},{"key":"1918_CR27","unstructured":"Australian Bureau of Statistics Technical Paper: Socio-Economic Indexes for Areas (SEIFA). 2033055001 2011."},{"key":"1918_CR28","unstructured":"World Health Organisation: Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organization technical report series 1995, 854:1\u2013452."},{"key":"1918_CR29","volume-title":"SF-12 : how to score the SF-12 physical and mental health summary scales","author":"JE Ware","year":"1998","unstructured":"Ware JE. SF-12 : how to score the SF-12 physical and mental health summary scales. 3rd ed. Lincoln, Boston: Quality Metric Inc. and the Health Assessment Lab; 1998.","edition":"3"},{"key":"1918_CR30","unstructured":"Avery J, Dal Grande, E., Taylor, A.: Quality of life in South Australia as measured by the SF12 Health Status Questionnaire. In Edited by Services DoH South Australia: South Australian Department of Human Services; 2004."},{"issue":"1","key":"1918_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12955-017-0806-6","volume":"15","author":"DA Gonzalez-Chica","year":"2017","unstructured":"Gonzalez-Chica DA, Hill CL, Gill TK, Hay P, Haag D, Stocks N. Individual diseases or clustering of health conditions? Association between multiple chronic diseases and health-related quality of life in adults. Health Qual Life Outcomes. 2017;15(1):244.","journal-title":"Health Qual Life Outcomes"},{"issue":"10","key":"1918_CR32","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1136\/ard.2007.070755","volume":"66","author":"E Roddy","year":"2007","unstructured":"Roddy E, Zhang W, Doherty M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann Rheum Dis. 2007;66(10):1311\u20135.","journal-title":"Ann Rheum Dis"},{"key":"1918_CR33","first-page":"13","volume":"47","author":"H Pisaniello","year":"2017","unstructured":"Pisaniello H, Lester S, Gonzalez-Chica D, Longo M, Sharplin G, Dal Grande E, Gill T, Whittle S, Hill C. Prevalence and predictors of gout and allopurinol use, and their association with risk perception: results from a south Australian population-based study. Intern Med J. 2017;47:13\u20134.","journal-title":"Intern Med J"},{"key":"1918_CR34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/imj.12544","volume":"45","author":"P Robinson","year":"2015","unstructured":"Robinson P, Taylor W, Dalbeth N. Gout prevalence and quality of care in an australian general practice population. Intern Med J. 2015;45:13.","journal-title":"Intern Med J"},{"issue":"10","key":"1918_CR35","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum. 2011;63(10):3136\u201341.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1918_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10654-014-9927-y","volume":"30","author":"JM Wijnands","year":"2015","unstructured":"Wijnands JM, Viechtbauer W, Thevissen K, Arts IC, Dagnelie PC, Stehouwer CD, van der Linden S, Boonen A. Determinants of the prevalence of gout in the general population: a systematic review and meta-regression. Eur J Epidemiol. 2015;30(1):19\u201333.","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"1918_CR37","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3899\/jrheum.100418","volume":"38","author":"MA McAdams","year":"2011","unstructured":"McAdams MA, Maynard JW, Baer AN, Kottgen A, Clipp S, Coresh J, Gelber AC. Reliability and sensitivity of the self-report of physician-diagnosed gout in the campaign against cancer and heart disease and the atherosclerosis risk in the community cohorts. J Rheumatol. 2011;38(1):135\u201341.","journal-title":"J Rheumatol"},{"issue":"1","key":"1918_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13075-017-1390-1","volume":"19","author":"M Cadzow","year":"2017","unstructured":"Cadzow M, Merriman TR, Dalbeth N. Performance of gout definitions for genetic epidemiological studies: analysis of UK biobank. Arthritis Res Ther. 2017;19(1):181.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"1918_CR39","first-page":"299","volume":"45","author":"PC Robinson","year":"2016","unstructured":"Robinson PC, Stamp LK. The management of gout: much has changed. Aust Fam Physician. 2016;45(5):299\u2013302.","journal-title":"Aust Fam Physician"},{"issue":"5","key":"1918_CR40","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/rheumatology\/keq363","volume":"50","author":"D Rothenbacher","year":"2011","unstructured":"Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodriguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatol. 2011;50(5):973\u201381.","journal-title":"Rheumatol"},{"issue":"9","key":"1918_CR41","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/rheumatology\/key155","volume":"57","author":"Lieke E J M Scheepers","year":"2018","unstructured":"Scheepers L, Burden AM, Arts ICW, Spaetgens B, Souverein P, de Vries F, Boonen A. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the clinical practice research datalink (CPRD). Rheumatol. 2018;57(9):1641\u201350.","journal-title":"Rheumatology"},{"issue":"6","key":"1918_CR42","doi-asserted-by":"publisher","first-page":"e39321","DOI":"10.1371\/journal.pone.0039321","volume":"7","author":"T Lyngdoh","year":"2012","unstructured":"Lyngdoh T, Vuistiner P, Marques-Vidal P, Rousson V, Waeber G, Vollenweider P, Bochud M. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach. PLoS One. 2012;7(6):e39321.","journal-title":"PLoS One"},{"issue":"2","key":"1918_CR43","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/bcp.12799","volume":"81","author":"DF Wright","year":"2016","unstructured":"Wright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol. 2016;81(2):277\u201389.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1918_CR44","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/acr.22954","volume":"69","author":"UD Nguyen","year":"2017","unstructured":"Nguyen UD, Zhang Y, Louie-Gao Q, Niu J, Felson DT, LaValley MP, Choi HK. Obesity paradox in recurrent attacks of gout in observational studies: clarification and remedy. Arthritis Care Res. 2017;69(4):561\u20136.","journal-title":"Arthritis Care Res"},{"issue":"1","key":"1918_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12891-017-1465-9","volume":"18","author":"LR Harrold","year":"2017","unstructured":"Harrold LR, Etzel CJ, Gibofsky A, Kremer JM, Pillinger MH, Saag KG, Schlesinger N, Terkeltaub R, Cox V, Greenberg JD. Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord. 2017;18(1):108.","journal-title":"BMC Musculoskelet Disord"},{"key":"1918_CR46","doi-asserted-by":"crossref","unstructured":"Mackey C, Diercks DB. Gender bias in the management of patients still exists. Acad Emerg Med Off J Soc Acad Emerg Med. 2018.","DOI":"10.1111\/acem.13394"},{"key":"1918_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/607472","volume":"2015","author":"Catherine L. Hill","year":"2015","unstructured":"Hill CL, Appleton SL, Black J, Hoon E, Rudd RE, Adams RJ, Gill T. Role of health literacy in self-reported musculoskeletal disorders. Arthritis. 2015;2015:607472.","journal-title":"Arthritis"},{"key":"1918_CR48","doi-asserted-by":"crossref","unstructured":"Gaffo AL, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, Chen YH, Lin CT, Bourke S, Louthrenoo W, et al. Validation of a definition of flare in patients with established gout. Arthritis Rheumatol. 2018;70(3):462-7.","DOI":"10.1002\/art.40381"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1918-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-019-1918-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-019-1918-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T23:20:36Z","timestamp":1590794436000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-019-1918-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1918"],"URL":"https:\/\/doi.org\/10.1186\/s13075-019-1918-7","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,31]]},"assertion":[{"value":"29 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The questionnaire and methodology for this study was approved by the Human Research Ethics committee of the University of Adelaide (Ethics number approval number: H-097-2010). Verbal informed consent was obtained prior to the interview.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual data were presented in any form in this study, and therefore, consent to publish is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Professor Dalbeth: research grant funding from Amgen and AstraZeneca\/Ironwood, speaker fees from Pfizer, Janssen, and Abbvie, and consulting fees from Horizon and Kowa.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"132"}}